Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- General Dermatology
- Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
Psoriasis Summit
San Francisco - While the 2002 Psoriasis Therapies Educational Summit Meeting successfully fostered various educational programs about new and emerging modalities for psoriasis treatment, many questions still linger, Jeffrey P. Callen, M.D., told attendees of the annual meeting of the American Academy of Dermatology. Specifically, questions regarding the use of biologic agents remain unable to be answered, Dr. Callen said.
Related Videos
Related Content
